Journal
CLINICAL CANCER RESEARCH
Volume 22, Issue 18, Pages 4539-4541Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-16-1401
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA195720, P50 CA196530] Funding Source: Medline
Ask authors/readers for more resources
Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. (C) 2016 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
